Correction: Targeting DORIS Remission and LLDAS in SLE: A Review

• Agner R. Parra Sánchez,
• Ronald F. van Vollenhoven,
• Eric F. Morand,
• Ian N. Bruce,
• Rangi Kandane-Rathnayake,
• Gudrun Weiss,
• Raj Tummala,
• Hussein Al-Mossawi,
• Alessandro Sorrentino

Affiliations

Agner R. Parra Sánchez

Amsterdam Rheumatology Center ARC, Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centre

Ronald F. van Vollenhoven

Amsterdam Rheumatology Center ARC, Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centre

Eric F. Morand

Sub-Faculty of Clinical and Molecular Medicine, Monash University

Ian N. Bruce

Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester

Rangi Kandane-Rathnayake

Sub-Faculty of Clinical and Molecular Medicine, Monash University

Gudrun Weiss

Global Medical Affairs, Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca

Raj Tummala

Clinical Development, Late Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca

Hussein Al-Mossawi

Clinical Development, Late Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca

Alessandro Sorrentino

Global Medical Affairs, Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca